The constitutive activation of NF-κB is a hallmark of most human tumors, including AML, where it promotes cell survival and resistance to therapy by activating anti-apoptotic genes and promoting inflammation in the tumor microenvironment (TME) [15,16]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.